Inactive Instrument

Prometheus Biosciences, Inc.

Equities

RXDX

US74349U1088

Biotechnology & Medical Research

Prometheus Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023

May 10, 2023 at 02:04 am IST

Prometheus Biosciences, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 40.88 million compared to USD 32.07 million a year ago. Basic loss per share from continuing operations was USD 0.86 compared to USD 0.82 a year ago.

Latest news about Prometheus Biosciences, Inc.

S&P 500 Posts Weekly Decline Led by Real Estate, Energy as Fed Officials Point to More Rate Increases	24/23/24	MT
Prometheus Biosciences, Inc.(NasdaqGS:RXDX) dropped from S&P Global BMI Index	21/23/21	CI
Prometheus Biosciences, Inc.(NasdaqGS:RXDX) dropped from S&P TMI Index	21/23/21	CI
Prometheus Biosciences, Inc.(NasdaqGS:RXDX) dropped from S&P Biotechnology Select Industry Index	21/23/21	CI
Global markets live: Adobe, Eli Lilly, Nasdaq, Intel, UBS...	20/23/20
Paris-listed Drugmaker Merck & Co. Buys Prometheus Biosciences	19/23/19	MT
Prometheus Biosciences, Inc.(NasdaqGM:) dropped from NASDAQ Composite Index	19/23/19	CI
Prometheus Biosciences, Inc.(NasdaqGS:RXDX) dropped from NASDAQ Biotechnology Index	19/23/19	CI
Merck & Company Completes Acquisition of Prometheus Biosciences for $10.8 Billion in Cash; to Cut EPS Outlook in August	17/23/17	MT
Prometheus Biosciences, Inc. Announces Management Changes	16/23/16	CI
Prometheus Biosciences, Inc. Announces Cessation of Mark C. McKenna as CEO	16/23/16	CI
Prometheus Biosciences, Inc. Announces Cessation of Keith W. Marshall as CFO	16/23/16	CI
Merck & Co., Inc. completed the acquisition of Prometheus Biosciences, Inc. from a group of shareholders.	16/23/16	CI
Analysis-Amgen's antitrust woes spur wider pharmaceutical deal fears	17/23/17	RE
US FTC sues to block Amgen's $27.8 bln deal for Horizon Therapeutics	17/23/17	RE
North American Morning Briefing : Stock Futures -3-	11/23/11	DJ
Jefferies Downgrades Prometheus Biosciences to Hold From Buy, Adjusts Price Target to $200 From $160	10/23/10	MT
Prometheus Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	10/23/10	CI
Earnings Flash (RXDX) PROMETHEUS BIOSCIENCES Reports Q1 Revenue $1.1M	10/23/10	MT
Merck & Co. Files Six-Part Shelf Offering of Unsecured Senior Debt Obligation Notes	08/23/08	MT
Drugmakers scout for deals, ramp up research spending	28/23/28	RE
North American Morning Briefing : Sentiment -3-	19/23/19	DJ
Global markets live: EasyJet, Bank of America, Goldman Sachs, J&J, Alphabet...	18/23/18
Credit Suisse Downgrades Prometheus Biosciences to Neutral From Outperform on Heels of Announced Sale to Merck & Co., Raises Price Target to $200 From $139	18/23/18	MT
RBC Downgrades Prometheus Biosciences to Sector Perform From Outperform, Lifts Price Target to $200 From $140 on Merck Deal; Speculative Risk Kept	18/23/18	MT

Chart Prometheus Biosciences, Inc.

Duration

Period

More charts

Company Profile

Prometheus Biosciences, Inc. is a clinical-stage biotechnology company. The Company discovers, develops and commercializes therapeutic products for the treatment of immune-mediated diseases, inflammatory bowel disease. Its precision medicine platform, Prometheus360, includes gastrointestinal bioinformatics databases and sample biobanks, to identify therapeutic targets, develop therapeutic candidates to engage those targets, and develop genetics-based diagnostic tests designed to identify patients to respond to its therapeutic candidates. Its lead product candidate, PRA023, is a humanized IgG1 monoclonal antibody (mAb) that has been shown to block the tumor necrosis factor (TNF). Its second product candidate, PRA052, is an anti-CD30L mAb. The CD30L-CD30 co-stimulatory pathway has been implicated in IBD by genetic, preclinical and human translational data. Its PR1100 program targets the receptor for a pro-inflammatory cytokine that has been linked to multiple immune-mediated diseases.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+22.56%	46.4B
IQVIA HOLDINGS INC.	-1.51%	41.75B
LONZA GROUP AG	+48.83%	41.37B
CELLTRION, INC.	-3.42%	29.71B
ICON PUBLIC LIMITED COMPANY	+10.13%	26.01B
ALNYLAM PHARMACEUTICALS, INC.	-20.44%	19.52B
MEDPACE HOLDINGS, INC.	+26.45%	12.43B
BIO-TECHNE CORPORATION	-0.14%	12.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.47%	12.13B

Other Biotechnology & Medical Research